Antitumor Vaccination with Synthetic mRNA: Strategies for In Vitro and In Vivo Preclinical Studies
- 8 November 2012
- book chapter
- Published by Springer Nature
- Vol. 969, 235-246
- https://doi.org/10.1007/978-1-62703-260-5_15
Abstract
Synthetic antigen-encoding mRNA is increasingly exploited as a tool for delivery of genetic information of complete antigens into professional antigen presenting dendritic cells for HLA haplotype-independent antigen-specific vaccination against cancer. Two strategies for mRNA-based antitumor vaccination have emerged into the clinical setting. One is transfection of autologous dendritic cells with synthetic mRNA for adoptive transfer into the patient. The other is direct injection of naked synthetic mRNA. Both methods have proven to be feasible and safe and to elicit antigen-specific immune responses. The design of novel synthetic vaccines employing synthetic mRNA requires further in-depth investigation of its bioavailability and immune pharmacology. This chapter summarizes the state-of-art in this field and describes methods elementary for preclinical studies of mRNA-based antitumor vaccine protocols.Keywords
This publication has 22 references indexed in Scilit:
- Tumor vaccination using messenger RNA: prospects of a future therapyCurrent Opinion in Immunology, 2011
- Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated PatientsMolecular Therapy, 2011
- Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivoGene Therapy, 2010
- Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma PatientsJournal of Immunotherapy, 2009
- Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNAJournal of Immunotherapy, 2008
- Intralymphatic Dendritic Cell Vaccination Induces Tumor Antigen–Specific, Skin-Homing T LymphocytesClinical Cancer Research, 2006
- Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNAImmunity, 2005
- Synergy between tumor immunotherapy and antiangiogenic therapyBlood, 2003
- Induction of Anti-Tumor Immunity with Epidermal Cells Pulsed with Tumor-Derived RNA or Intradermal Administration of RNAJournal of Investigative Dermatology, 2000
- Direct Gene Transfer into Mouse Muscle in VivoScience, 1990